Susquehanna International Group, LLP Bio Line Rx Ltd. Transaction History
Susquehanna International Group, LLP
- $527 Billion
- Q2 2024
A detailed history of Susquehanna International Group, LLP transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 118,180 shares of BLRX stock, worth $54,362. This represents 0.0% of its overall portfolio holdings.
Number of Shares
118,180
Previous 204,914
42.33%
Holding current value
$54,362
Previous $229,000
70.74%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding BLRX
# of Institutions
37Shares Held
4.29MCall Options Held
49.9KPut Options Held
122K-
Alyeska Investment Group, L.P. Chicago, IL1.95MShares$898,5480.01% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$375,2144.05% of portfolio
-
Envestnet Asset Management Inc214KShares$98,3630.0% of portfolio
-
Values First Advisors, Inc.204KShares$93,7290.07% of portfolio
-
Pvg Asset Management Corp Golden, CO124KShares$56,8460.3% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $28.3M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...